抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展

Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents

肝癌是严重威胁人类健康的消化系统恶性肿瘤之一。在我国,其发病率位居第四位,死亡率高居第二位。手术治疗有自身局限性,常规化疗药物作用有限,毒副作用大,且没有明显的生存获益。分子靶向治疗能选择性地杀灭肿瘤细胞,对机体的损伤较小,是近年来肿瘤治疗领域新的研究方向。小分子酪氨酸激酶抑制剂(TKIs)作为一类分子靶向药物,已成为当前抗肝癌研究的主流趋势之一。本文主要对已上市和正在进行临床试验的小分子酪氨酸激酶抑制剂抗肝癌最新临床情况作一综述。

Liver cancer is one kind of the digestive system cancer which is seriously threatening the health of human.The incidence and mortality of liver cancer rank as the fourth and second in China,respectively.Surgical treatment has its own limitations,and conventional chemotherapy drugs have severe side effects with no obvious survival benefits.In recent years,molecular targeted therapy,which can selectively kill tumor cells and has less damage to the body,has been a new research direction in the field of tumor therapy.Small molecule tyrosine kinase inhibitors(TKIs),a family of molecular targeted drugs,have become one of the mainstreams in anti-hepatocarcinoma research.In this paper we briefly summarize the latest clinical trials of small molecule tyrosine kinase inhibitors,including those both on the market and in clinical trials.